PDCD1 and neoplasm: In ccRCC, the low intratumor heterogeneity, which is the genetic diversity of subclones in a single tumor, could promote the antigen presentation to T cells by enhancing the immune activity of new tumor antigens, the abundance of DCs, and the expression of HLA class I gene, and ultimately improve the response to PD‐1 blockade.99